HROW
Price
$38.80
Change
-$0.18 (-0.46%)
Updated
Aug 29, 04:03 PM (EDT)
Capitalization
1.44B
80 days until earnings call
INDV
Price
$24.05
Change
+$0.17 (+0.71%)
Updated
Aug 29, 04:04 PM (EDT)
Capitalization
2.98B
55 days until earnings call
Interact to see
Advertisement

HROW vs INDV

Header iconHROW vs INDV Comparison
Open Charts HROW vs INDVBanner chart's image
Harrow
Price$38.80
Change-$0.18 (-0.46%)
Volume$100
Capitalization1.44B
Indivior
Price$24.05
Change+$0.17 (+0.71%)
Volume$300
Capitalization2.98B
HROW vs INDV Comparison Chart in %
Loading...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INDV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HROW vs. INDV commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a StrongBuy and INDV is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (HROW: $38.99 vs. INDV: $23.88)
Brand notoriety: HROW and INDV are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HROW: 59% vs. INDV: 43%
Market capitalization -- HROW: $1.44B vs. INDV: $2.98B
HROW [@Pharmaceuticals: Generic] is valued at $1.44B. INDV’s [@Pharmaceuticals: Generic] market capitalization is $2.98B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HROW’s FA Score shows that 0 FA rating(s) are green whileINDV’s FA Score has 0 green FA rating(s).

  • HROW’s FA Score: 0 green, 5 red.
  • INDV’s FA Score: 0 green, 5 red.
According to our system of comparison, HROW is a better buy in the long-term than INDV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HROW’s TA Score shows that 5 TA indicator(s) are bullish while INDV’s TA Score has 2 bullish TA indicator(s).

  • HROW’s TA Score: 5 bullish, 5 bearish.
  • INDV’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, HROW is a better buy in the short-term than INDV.

Price Growth

HROW (@Pharmaceuticals: Generic) experienced а +2.18% price change this week, while INDV (@Pharmaceuticals: Generic) price change was -0.71% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.15%. For the same industry, the average monthly price growth was +68.06%, and the average quarterly price growth was +81.85%.

Reported Earning Dates

HROW is expected to report earnings on Nov 17, 2025.

INDV is expected to report earnings on Oct 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INDV($2.98B) has a higher market cap than HROW($1.44B). INDV YTD gains are higher at: 92.116 vs. HROW (16.215). INDV has higher annual earnings (EBITDA): 261M vs. HROW (32.1M). INDV has more cash in the bank: 510M vs. HROW (53M). HROW has less debt than INDV: HROW (231M) vs INDV (366M). INDV has higher revenues than HROW: INDV (1.17B) vs HROW (228M).
HROWINDVHROW / INDV
Capitalization1.44B2.98B48%
EBITDA32.1M261M12%
Gain YTD16.21592.11618%
P/E RatioN/A29.48-
Revenue228M1.17B19%
Total Cash53M510M10%
Total Debt231M366M63%
FUNDAMENTALS RATINGS
HROW vs INDV: Fundamental Ratings
HROW
INDV
OUTLOOK RATING
1..100
1889
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
4752
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4135
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HROW's Valuation (84) in the Pharmaceuticals Other industry is in the same range as INDV (94) in the null industry. This means that HROW’s stock grew similarly to INDV’s over the last 12 months.

HROW's Profit vs Risk Rating (47) in the Pharmaceuticals Other industry is in the same range as INDV (52) in the null industry. This means that HROW’s stock grew similarly to INDV’s over the last 12 months.

HROW's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as INDV (100) in the null industry. This means that HROW’s stock grew similarly to INDV’s over the last 12 months.

INDV's Price Growth Rating (35) in the null industry is in the same range as HROW (41) in the Pharmaceuticals Other industry. This means that INDV’s stock grew similarly to HROW’s over the last 12 months.

INDV's P/E Growth Rating (100) in the null industry is in the same range as HROW (100) in the Pharmaceuticals Other industry. This means that INDV’s stock grew similarly to HROW’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HROWINDV
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 5 days ago
51%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 5 days ago
60%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 10 days ago
72%
Declines
ODDS (%)
Bearish Trend 12 days ago
80%
Bearish Trend 2 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
62%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INDV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USLIX75.60N/A
N/A
JHancock U.S. Global Leaders Growth I
GSAEX26.08N/A
N/A
Goldman Sachs China Equity Inv
JVAQX40.61N/A
N/A
JPMorgan Value Advantage R4
GQHPX13.39N/A
N/A
GQG Partners US Quality Value Fund Inv
IARIX16.89N/A
N/A
Invesco Real Estate R5

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+0.52%
AQST - HROW
33%
Loosely correlated
-0.52%
OGI - HROW
33%
Loosely correlated
+3.59%
TKNO - HROW
31%
Poorly correlated
-3.15%
AMRX - HROW
31%
Poorly correlated
+2.03%
VTRS - HROW
30%
Poorly correlated
-0.10%
More

INDV and

Correlation & Price change

A.I.dvisor tells us that INDV and CAIHF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INDV and CAIHF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INDV
1D Price
Change %
INDV100%
-1.97%
CAIHF - INDV
27%
Poorly correlated
N/A
ASRT - INDV
26%
Poorly correlated
+5.32%
ALKS - INDV
25%
Poorly correlated
-1.09%
MKKGY - INDV
24%
Poorly correlated
-0.10%
HROW - INDV
24%
Poorly correlated
+0.52%
More